David Auregan - Theradiag Chief Officer

All Insiders . France . 
Stock . Theradiag SA . Stakeholders . Insider . David Auregan
ALTHE Stock  EUR 0.37  0.03  8.82%   

Insider

David Auregan is Chief Officer of Theradiag SA
Phone33 1 55 48 90 70
Webhttps://www.theraclion.com

Theradiag Management Efficiency

The company has return on total asset (ROA) of (0.2533) % which means that it has lost $0.2533 on every $100 spent on assets. This is way below average. Theradiag's management efficiency ratios could be used to measure how well Theradiag manages its routine affairs as well as how well it operates its assets and liabilities.
Theradiag SA has accumulated 2.05 M in total debt with debt to equity ratio (D/E) of 909.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Theradiag SA has a current ratio of 1.6, which is within standard range for the sector. Debt can assist Theradiag until it has trouble settling it off, either with new capital or with free cash flow. So, Theradiag's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theradiag SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theradiag to invest in growth at high rates of return. When we think about Theradiag's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Heiko ImhlSartorius Stedim Biotech
N/A
Pierre BouludBiomerieux SA
52
Gabriel JuliaEurofins Scientific SE
N/A
Sylvain MorgeauBiomerieux SA
N/A
Benedikt OrzelekSartorius Stedim Biotech
N/A
Philippe SchailleeSEB SA
N/A
Franois LacosteBiomerieux SA
N/A
Isabelle PosthSEB SA
N/A
Cyril BuxtorfSEB SA
57
Cathy PianonSEB SA
N/A
Olivier GuitardSartorius Stedim Biotech
N/A
Petra KirchhoffSartorius Stedim Biotech
54
Valerie HanoteEurofins Scientific SE
57
Valerie LeyldeBiomerieux SA
N/A
Guillaume BouhoursBiomerieux SA
47
Pierre CharbonnierBiomerieux SA
N/A
Mark MillerBiomerieux SA
N/A
Alexandre MerieuxBiomerieux SA
49
Sandra HoeylaertsEurofins Scientific SE
N/A
Stanislas GramontSEB SA
57
Joachim KreuzburgSartorius Stedim Biotech
58
Theraclion SA develops, manufactures, and markets Echopulse ultrasound medical imaging tool for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners. The company was founded in 2004 and is based in Malakoff, France. THERACLION operates under Medical Devices classification in France and is traded on Paris Stock Exchange. It employs 22 people. Theradiag SA (ALTHE) is traded on Euronext Paris in France and employs 28 people.

Management Performance

Return On Asset-0.25

Theradiag SA Leadership Team

Elected by the shareholders, the Theradiag's board of directors comprises two types of representatives: Theradiag inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theradiag. The board's role is to monitor Theradiag's management team and ensure that shareholders' interests are well served. Theradiag's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theradiag's outside directors are responsible for providing unbiased perspectives on the board's policies.
Yann Duchesne, Ex Chairman
Roberta Brocardo, Ex Officer
Jose AbellanMartinez, VP Devel
Anja Kleber, VP Access
David Auregan, Chief Officer
Gaylord Tallec, Director Operations
Michel MD, VP Officer

Theradiag Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theradiag a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.25
Operating Margin(8.41) %
Current Valuation20.58 M
Shares Outstanding28.8 M
Shares Owned By Insiders22.50 %
Shares Owned By Institutions7.88 %
Price To Book10.04 X
Price To Sales34.41 X
Revenue1.48 M
Gross Profit(1.4 M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Theradiag Stock Analysis

When running Theradiag's price analysis, check to measure Theradiag's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theradiag is operating at the current time. Most of Theradiag's value examination focuses on studying past and present price action to predict the probability of Theradiag's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theradiag's price. Additionally, you may evaluate how the addition of Theradiag to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY